| Old Articles: <Older 2921-2930 Newer> |
|---|
 |
The Motley Fool
May 26, 2006
Brian Gorman |
AstraZeneca's Essential Investment The drugmaker seems to be jumping on the China bandwagon, but its investment makes sense, given the potential return.   |
The Motley Fool
May 24, 2006
S.J. Caplan |
Goodbye, Guidant Publicity woes drive Boston Scientific to ditch the Guidant name. In the meantime, Boston Scientific wants to capitalize on its entry into the ICD market, an area experiencing double-digit sales growth. Investors, take note. |
The Motley Fool
May 23, 2006
Stephen D. Simpson |
HealthSouth Still in Rehab Rendered almost incapacitated by one of the larger frauds of the Bubble Era, the rehab specialist is hoping to emerge from the ashes, justifying the patience of long-suffering employees and whatever long-term investors have hung on throughout this whole mess. |
The Motley Fool
May 23, 2006
Rich Duprey |
Eisai Has a Yen for Profits With new formulations for its current drugs planned for release, expansion of its blockbuster drug Aricept possible, and with a few new drugs in the pipeline, the Japanese pharmaceutical is poised to continue churning out record revenues and earnings that investors won't soon forget. |
The Motley Fool
May 22, 2006
Stephen D. Simpson |
Nektar Full of Potential, Risk Can inhaled insulin sales live up to investors' expectations at Nektar Therapeutics? |
National Defense
June 2006
Robert H. Williams |
First Responder Testing Kits Offered Chemical-biological kits for first responders have been upgraded by QuickSilver Analytics, to include radiological and explosive sampling capabilities. |
BusinessWeek
May 29, 2006
John Carey |
Medical Guesswork From heart surgery to prostate care, the health industry knows little about which common treatments really work. |
BusinessWeek
May 29, 2006
Howard Gleckman |
Medicine's Industrial Revolution Medical treatments that are proven to work reach only about half of the Americans who need them, according to a series of studies by RAND Corp. And in hospitals, simple measures that protect patients' lives are often hard to implement. |
BusinessWeek
May 29, 2006
John Carey |
When More Medicine Is Less A Dartmouth study finds a greater risk of death among patients treated in high-cost hospitals and clinics - and highlights conflicts of interest. |
The Motley Fool
May 17, 2006
Stephen D. Simpson |
Angiotech Pharmaceuticals: Rebuilding or Reloading? This small Canadian drug-delivery outfit is reshaping and diversifying. Investors, is it time to buy? |
| <Older 2921-2930 Newer> Return to current articles. |
